Lianne Kearsley-Fleet
Overview
Explore the profile of Lianne Kearsley-Fleet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kearsley-Fleet L, Smith S, Ramanan A, Hyrich K
Ann Rheum Dis
. 2025 Feb;
84(3):375-381.
PMID: 39939278
No abstract available.
2.
Hamoodi Z, Sayers A, Whitehouse M, Rangan A, Kearsley-Fleet L, Sergeant J, et al.
Bone Joint J
. 2024 Oct;
106-B(11):1312-1320.
PMID: 39481433
Aims: The aim of this study was to review the provision of total elbow arthroplasties (TEAs) in England, including the incidence, the characteristics of the patients and the service providers,...
3.
Studenic P, Meissner Y, Kearsley-Fleet L, De Cock D
Best Pract Res Clin Rheumatol
. 2024 Oct;
39(1):102017.
PMID: 39406599
Rheumatoid arthritis (RA) is one of the most common rheumatic conditions, impacting quality of life on several domains. Major breakthroughs have been achieved over the past three decades in the...
4.
Tsoi M, Kearsley-Fleet L, Azadbakht N, Watson K, Hyrich K, Bluett J
Rheumatology (Oxford)
. 2024 Sep;
64(2):477-483.
PMID: 39276163
Objectives: Tocilizumab is an IL-6 receptor humanized monoclonal antibody for the treatment of rheumatoid arthritis (RA) with intravenous (IV) and subcutaneous (SC) preparations available. Only IV tocilizumab is dosed adjusting...
5.
Hamoodi Z, Sayers A, Whitehouse M, Rangan A, Kearsley-Fleet L, Sergeant J, et al.
J Orthop Surg Res
. 2024 Aug;
19(1):526.
PMID: 39215301
Introduction: Primary total elbow replacement (TER) services in England are being restructured with the goal of centralising care to specialised centres. It is important to monitor the impact of this...
6.
Kearsley-Fleet L, Baildam E, Beresford M, Douglas S, Foster H, Southwood T, et al.
Lancet Rheumatol
. 2024 Jun;
6(7):e438-e446.
PMID: 38843858
Background: For cost-saving purposes, children and young people with juvenile idiopathic arthritis (JIA) are being switched (for non-medical reasons) from biological originators to biosimilars. Here, we aimed to investigate those...
7.
Tian Z, Kearsley-Fleet L, Galloway J, Watson K, Lunt M, Hyrich K
Rheumatology (Oxford)
. 2024 May;
64(3):1453-1458.
PMID: 38748995
Objective: Janus kinase inhibitors (JAKis) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) effectively treat rheumatoid arthritis (RA). However, due to safety concerns, the European Medicines Agency (EMA) published risk-minimization...
8.
Hamoodi Z, Gehringer C, Bull L, Hughes T, Kearsley-Fleet L, Sergeant J, et al.
Bone Joint Res
. 2024 Apr;
13(5):201-213.
PMID: 38688503
Aims: The aims of this study were to identify and evaluate the current literature examining the prognostic factors which are associated with failure of total elbow arthroplasty (TEA). Methods: Electronic...
9.
Mannion M, Amin S, Balevic S, Chang M, Correll C, Kearsley-Fleet L, et al.
Arthritis Care Res (Hoboken)
. 2024 Apr;
76(8):1090-1098.
PMID: 38556945
Objective: The objective of this study was to compare the effectiveness of a second tumor necrosis factor inhibitor (TNFi) versus a non-TNFi biologic following discontinuation of a TNFi for patients...
10.
Aymon R, Mongin D, Bergstra S, Choquette D, Codreanu C, De Cock D, et al.
Ann Rheum Dis
. 2023 Dec;
83(4):421-428.
PMID: 38071508
Background: In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis...